logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Boston Biomedical, Inc.


USPTO Granted Patents = 19

% Expired Patents = 94.7



Trademarks = 2

Forward Citations = 50

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Chiang Jia Li (18 out of 57 patents)

silverMedal Wei Li (13 out of 16 patents)

bronzeMedal Youzhi Li (11 out of 22 patents)

4.  David Leggett (8 out of 9 patents)

5.  Harry Rogoff (4 out of 9 patents)

6.  Ji-Feng Liu (3 out of 3 patents)

7.  Hitoshi Ban (2 out of 41 patents)

8.  Seiji Kamioka (2 out of 18 patents)

9.  Yusuke Sawayama (2 out of 7 patents)

10.  Naoaki Shimada (2 out of 29 patents)

11.  Wataru Hirose (2 out of 10 patents)

12.  Zhiwei Jiang (2 out of 9 patents)

13.  Toshihiko Sone (2 out of 3 patents)

14.  Matthew Hitron (2 out of 2 patents)

15.  Keith Mikule (2 out of 2 patents)


19 patents:

1. 10800752 - Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer (2020-10-13),
2. 10683274 - 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof (2020-06-16),
3. 10646464 - Methods for treating cancer (2020-05-12),
4. 10543189 - 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer (2020-01-28),
5. 10377731 - Compositions and methods for cancer treatment (2019-08-13),
6. 10183925 - Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer (2019-01-22),
7. 10017488 - 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof (2018-07-10),
8. 9834532 - Stat3 pathway inhibitors and cancer stem cell inhibitors (2017-12-05),
9. 9795595 - Methods for treating cancer (2017-10-24),
10. 9745278 - Group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors (2017-08-29),
11. 9732055 - Compositions and methods for cancer treatment (2017-08-15),
12. 9730909 - Methods for targeting cancer stem cells (2017-08-15),
13. 9725444 - Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases (2017-08-08),
14. 9381184 - Compounds and compositions for targeting cancer stem cells (2016-07-05),
15. 9227962 - Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative (2016-01-05),
Company Overview
Boston Biomedical, Inc. is a biotechnology company based in Cambridge, MA, specializing in the development of innovative cancer therapies. The organization focuses on advancing targeted treatments that aim to improve patient outcomes in oncology. With a commitment to research and development, Boston Biomedical leverages cutting-edge technologies to explore novel therapeutic approaches, particularly in the realm of precision medicine. Their work is pivotal in addressing unmet medical needs in cancer care.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

19 Patents

#145 in Cambridge, MA

#1,049 in Massachusetts

#17,138 in US

#32,663 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Boston Biomedical, Inc.

Forward Citations = 50

25 inventors:

goldMedal Chiang Jia Li (18 out of 57 patents)

silverMedal Wei Li (13 out of 16 patents)

bronzeMedal Youzhi Li (11 out of 22 patents)

4.  David Leggett (8 out of 9 patents)

5.  Harry Rogoff (4 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Boston Biomedical, Inc.. Retrieved from https://idiyas.com/company/boston-biomedical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…